{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T01:39:16Z","timestamp":1768786756248,"version":"3.49.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,10,6]],"date-time":"2010-10-06T00:00:00Z","timestamp":1286323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2010,10,6]],"date-time":"2010-10-06T00:00:00Z","timestamp":1286323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s10637-010-9546-8","type":"journal-article","created":{"date-parts":[[2010,10,5]],"date-time":"2010-10-05T04:24:54Z","timestamp":1286252694000},"page":"611-615","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials"],"prefix":"10.1007","volume":"30","author":[{"given":"Stephane","family":"Ederhy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Massard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghislaine","family":"Dufaitre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ratio","family":"Balheda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Meuleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Gomez","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassane","family":"Izzedine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Charles","family":"Soria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,10,6]]},"reference":[{"key":"9546_CR1","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1056\/NEJMra044389","volume":"353","author":"DS Krause","year":"2005","unstructured":"Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353:172\u2013187","journal-title":"N Engl J Med"},{"key":"9546_CR2","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrc2403","volume":"8","author":"LM Ellis","year":"2008","unstructured":"Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8:579\u2013591","journal-title":"Nat Rev Cancer"},{"key":"9546_CR3","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nrc2106","volume":"7","author":"T Force","year":"2007","unstructured":"Force T, Krause DS, Van Etten RA (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7:332\u2013344","journal-title":"Nat Rev Cancer"},{"key":"9546_CR4","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/ncponc1225","volume":"5","author":"AY Khakoo","year":"2008","unstructured":"Khakoo AY, Yeh ET (2008) Therapy insight: management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nat Clin Pract Oncol 5:655\u2013667","journal-title":"Nat Clin Pract Oncol"},{"key":"9546_CR5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/ncpcardio1375","volume":"5","author":"IN Daher","year":"2008","unstructured":"Daher IN, Yeh ET (2008) Vascular complications of selected cancer therapies. Nat Clin Pract Cardiovasc Med 5:797\u2013805","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"9546_CR6","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","volume":"370","author":"TF Chu","year":"2007","unstructured":"Chu TF, Rupnick MA, Kerkela R et al (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370:2011\u20132019","journal-title":"Lancet"},{"key":"9546_CR7","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/nm1446","volume":"12","author":"R Kerkel\u00e4","year":"2006","unstructured":"Kerkel\u00e4 R, Grazette L, Yacobi R et al (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12:908\u2013916","journal-title":"Nat Med"},{"key":"9546_CR8","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1002\/cncr.23460","volume":"112","author":"AY Khakoo","year":"2008","unstructured":"Khakoo AY, Kassiotis CM, Tannir N et al (2008) Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 112:2500\u20132508","journal-title":"Cancer"},{"key":"9546_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM, TARGET Study Group et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125\u2013134","journal-title":"N Engl J Med"},{"key":"9546_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115\u2013124","journal-title":"N Engl J Med"},{"key":"9546_CR11","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659\u20131672","journal-title":"N Engl J Med"},{"key":"9546_CR12","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2000","unstructured":"Romond EH, Perez EA, Bryant J et al (2000) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673\u20131684","journal-title":"N Engl J Med"},{"key":"9546_CR13","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","volume":"26","author":"M Schmidinger","year":"2008","unstructured":"Schmidinger M, Zielinski CC, Vogl UM et al (2008) Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 26:5204\u20135212","journal-title":"J Clin Oncol"},{"key":"9546_CR14","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","volume":"109","author":"D Cardinale","year":"2004","unstructured":"Cardinale D, Sandri MT, Colombo A et al (2004) Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109:2749\u20132754","journal-title":"Circulation"},{"key":"9546_CR15","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/ncponc0663","volume":"3","author":"MM Cooney","year":"2006","unstructured":"Cooney MM, van Heeckeren W, Bhakta S et al (2006) Drug insight: vascular disrupting agents and angiogenesis\u2013novel approaches for drug delivery. Nat Clin Pract Oncol 3:682\u2013692","journal-title":"Nat Clin Pract Oncol"},{"issue":"Spec No 1","key":"9546_CR16","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1259\/bjr\/36205483","volume":"81","author":"GM Tozer","year":"2008","unstructured":"Tozer GM, Kanthou C, Lewis G et al (2008) Tumour vascular disrupting agents: combating treatment resistance. Br J Radiol 81(Spec No 1):S12\u2013S20","journal-title":"Br J Radiol"},{"key":"9546_CR17","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrc1628","volume":"5","author":"GM Tozer","year":"2005","unstructured":"Tozer GM, Kanthou C, Baguley BC (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5:423\u2013435","journal-title":"Nat Rev Cancer"},{"key":"9546_CR18","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/sj.bjc.6603694","volume":"96","author":"P Hinnen","year":"2007","unstructured":"Hinnen P, Eskens FA (2007) Vascular disrupting agents in clinical development. Br J Cancer 96:1159\u20131165","journal-title":"Br J Cancer"},{"key":"9546_CR19","doi-asserted-by":"crossref","unstructured":"Soria JC, Sessa C, Perotti A et al (2008) A comprehensive study of translational research and safety exploration of the vascular disrupting agent (VDA) AVE8062 in combination with cisplatin administered every 3\u00a0weeks to patients with advanced solid tumors. AACR Meeting Abstracts; 2008: LB-302, Apr","DOI":"10.1158\/1538-7445.AM2008-LB-302"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9546-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-010-9546-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9546-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9546-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:18:57Z","timestamp":1678558737000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-010-9546-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,6]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["9546"],"URL":"https:\/\/doi.org\/10.1007\/s10637-010-9546-8","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,6]]},"assertion":[{"value":"17 May 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}